JP7079779B2 - 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 - Google Patents

操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 Download PDF

Info

Publication number
JP7079779B2
JP7079779B2 JP2019526306A JP2019526306A JP7079779B2 JP 7079779 B2 JP7079779 B2 JP 7079779B2 JP 2019526306 A JP2019526306 A JP 2019526306A JP 2019526306 A JP2019526306 A JP 2019526306A JP 7079779 B2 JP7079779 B2 JP 7079779B2
Authority
JP
Japan
Prior art keywords
tgf
amino acid
residue
monomer
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019526306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500511A (ja
JP2020500511A5 (https=
Inventor
アンドリュー ピーターソン ヒンク，
トライアン スレア，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of JP2020500511A publication Critical patent/JP2020500511A/ja
Publication of JP2020500511A5 publication Critical patent/JP2020500511A5/ja
Priority to JP2021214183A priority Critical patent/JP7623273B2/ja
Application granted granted Critical
Publication of JP7079779B2 publication Critical patent/JP7079779B2/ja
Priority to JP2023160199A priority patent/JP2023164748A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019526306A 2016-11-18 2017-11-17 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 Active JP7079779B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021214183A JP7623273B2 (ja) 2016-11-18 2021-12-28 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用
JP2023160199A JP2023164748A (ja) 2016-11-18 2023-09-25 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423920P 2016-11-18 2016-11-18
US62/423,920 2016-11-18
PCT/US2017/062233 WO2018094173A1 (en) 2016-11-18 2017-11-17 Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021214183A Division JP7623273B2 (ja) 2016-11-18 2021-12-28 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用

Publications (3)

Publication Number Publication Date
JP2020500511A JP2020500511A (ja) 2020-01-16
JP2020500511A5 JP2020500511A5 (https=) 2020-11-19
JP7079779B2 true JP7079779B2 (ja) 2022-06-02

Family

ID=62146703

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019526306A Active JP7079779B2 (ja) 2016-11-18 2017-11-17 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用
JP2021214183A Active JP7623273B2 (ja) 2016-11-18 2021-12-28 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用
JP2023160199A Withdrawn JP2023164748A (ja) 2016-11-18 2023-09-25 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021214183A Active JP7623273B2 (ja) 2016-11-18 2021-12-28 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用
JP2023160199A Withdrawn JP2023164748A (ja) 2016-11-18 2023-09-25 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用

Country Status (6)

Country Link
US (2) US11091523B2 (https=)
EP (1) EP3541409B1 (https=)
JP (3) JP7079779B2 (https=)
ES (1) ES3011833T3 (https=)
PT (1) PT3541409T (https=)
WO (1) WO2018094173A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023164748A (ja) * 2016-11-18 2023-11-10 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220409684A1 (en) * 2019-11-18 2022-12-29 The Brigham And Women's Hospital, Inc. Codon optimized new generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
WO2022047220A1 (en) * 2020-08-27 2022-03-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses encoding recombinant tranforming growth factor (tgf)-beta monomers and uses thereof
WO2022139493A1 (ko) * 2020-12-23 2022-06-30 한국과학기술연구원 TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도
CN118103390A (zh) * 2021-10-11 2024-05-28 联邦高等教育系统匹兹堡大学 工程化TGF-β单体及其使用方法
JP2024096518A (ja) * 2023-01-03 2024-07-16 エフビーデー バイオロジクス リミテッド 操作されたｔｇｆｂｒｉｉバリアント及びその使用方法
JP2026503849A (ja) * 2023-01-30 2026-01-30 シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート 免疫細胞の機能を増強するための誘導型サイトカイン導入遺伝子
KR20260019369A (ko) 2023-05-31 2026-02-10 에프비디 바이올로직스 리미티드 Cd47/pd-l1-표적화 단백질 복합체 및 그의 사용 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503820A (ja) 2003-09-05 2007-03-01 ナショナル・リサーチ・カウンシル・オブ・カナダ 細胞レセプタードメインを含むコイルドコイル融合タンパク質
JP2015535000A (ja) 2012-11-09 2015-12-07 セントロ ド インムノロジア モレキュラー ＴＧＦβに由来するポリペプチド及びその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
WO2011094749A2 (en) 2010-02-01 2011-08-04 Board Of Regents, The University Of Texas System Small molecule inhibitors that block assembly of the tgf-beta signaling complex
WO2018094173A1 (en) 2016-11-18 2018-05-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503820A (ja) 2003-09-05 2007-03-01 ナショナル・リサーチ・カウンシル・オブ・カナダ 細胞レセプタードメインを含むコイルドコイル融合タンパク質
JP2015535000A (ja) 2012-11-09 2015-12-07 セントロ ド インムノロジア モレキュラー ＴＧＦβに由来するポリペプチド及びその使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023164748A (ja) * 2016-11-18 2023-11-10 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用

Also Published As

Publication number Publication date
CA3041727A1 (en) 2018-05-24
EP3541409A4 (en) 2020-06-17
ES3011833T3 (en) 2025-04-08
US20190359667A1 (en) 2019-11-28
JP2022033239A (ja) 2022-02-28
JP7623273B2 (ja) 2025-01-28
JP2020500511A (ja) 2020-01-16
US20210332096A1 (en) 2021-10-28
US12428460B2 (en) 2025-09-30
EP3541409A1 (en) 2019-09-25
US11091523B2 (en) 2021-08-17
PT3541409T (pt) 2025-02-13
EP3541409B1 (en) 2025-01-22
JP2023164748A (ja) 2023-11-10
WO2018094173A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
JP7079779B2 (ja) 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用
JP6860618B2 (ja) 抗補体Ｃ１ｓ抗体とそれらの用途
EP2867360B1 (en) Designed ankyrin repeat proteins binding to platelet-derived growth factor
US20170299608A1 (en) Compositions and methods for modulating body weight
US20140113348A1 (en) Meditopes and meditope-binding antibodies and uses thereof
TW201000118A (en) Multivalent fibronectin based scaffold domain proteins
JP2018511327A (ja) 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン
US10640549B2 (en) Recombinant antibodies that recognize the C-terminal domains of Ebola virus nucleoprotein
JP2016000731A (ja) 二重特異性ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP3423094A1 (en) Gfral receptor therapies
WO2012162426A1 (en) Methods and compositions for heptameric targeting ligands
CN105026422B (zh) Sh2结构域变体
JP2025523049A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びその使用
CN108883147A (zh) 用于治疗异常Wnt信号传送的稳定化BCL9肽
WO2015194831A1 (ko) TCTP 이량체형 IgE-의존성 히스타민 방출인자와 이의 수용체 간의 결합 억제제 및 이의 용도
JP2024149556A (ja) Ｖｅｇｆのためのｄ－ペプチド性化合物
JP2011526491A (ja) インスリン融合ポリペプチド
US20220267376A1 (en) P53 activator peptidomimetic macrocycles
CA3041727C (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
WO2014071234A1 (en) Gb1 peptidic compounds and methods for making and using the same
HK40015109A (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
HK40015109B (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
EP4267624A1 (en) Nanobody to glycoprotein vi
Geist et al. Computer-guided design of Z domain peptides with improved inhibition of VEGF
WO2014194267A2 (en) Wnt peptide pharmacophore compositions and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220426

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220523

R150 Certificate of patent or registration of utility model

Ref document number: 7079779

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250